There are so many ways you can help make a difference in the lives of patients and families today.
This award from the Brain Tumour Foundation of Canada is a tremendous honour for myself and my laboratory, where it allows us to spearhead important translational work in very high-risk medulloblastoma that we hope can one day benefit patients and their families.
Thanks to the generous funding provided by the Brain Tumour Foundation of Canada and DUNN with Cancer, we are now poised to advance our research and delve deeper into elucidating key epigenetic factors that drive the progression of GBM and its resistance to therapies.
Cancer treatment has undergone many advancements in the past decade to improve patient quality of life and to provide new and improved treatment strategies. However, there is still a lot of work to be done, with current treatment strategies succumbing to resistance, and other more rare cancers remaining undruggable.